Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Clinical Trials
Episode 39 with Dr. Joseph Berger on diagnostic dilemmas in MS
Episode 23 with Professor Aksel Siva discussing radiologically isolated syndrome (RIS)
[Usefulness of electronic drug registers: Spanish register of patients treated with fingolimod (Gilenya ®)].
Effects of delayed-release dimethyl fumarate on MRI measures in the phase 3 CONFIRM study.
Natalizumab strongly suppresses cortical pathology in relapsing-remitting multiple sclerosis.
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
The MS Microbiome Consortium (MSMC): an academic multi-disciplinary collaborative effort to elucidate the role of the gut microbiota in MS
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID).
Therapeutic plasma exchange and pregnancy: A case report and guidelines for performing plasma exchange in a pregnant patient.
Neuroprotection mediated through estrogen receptor-alpha in astrocytes.
Best practice in the use of natalizumab in multiple sclerosis.
Management of worsening multiple sclerosis with mitoxantrone: a review.
Nancy Davis Foundation Annual MS Expo and Health Forum
Teriflunomide modest help but safe for MS
Birth Outcomes in Newborns Fathered by Men with Multiple Sclerosis Exposed to Disease-Modifying Drugs.
Biogen Presents New Anti-LINGO-1 Phase 2 Acute Optic Neuritis Data Demonstrating Neurological Repair
Suppressed RNA-Polymerase 1 Pathway Is Associated with Benign Multiple Sclerosis.
IL-2Rβγ-signaling contributes to regulatory T cell maintenance and stability in daclizumab HYP-treated RRMS patients
Evaluation of No Evidence of Disease Activity in a 7-Year Longitudinal Multiple Sclerosis Cohort.
Macrophage depletion impairs oligodendrocyte remyelination following lysolecithin-induced demyelination.
Sex differences in autoimmune disease.
Treatment Choices in Optic Neuritis: Corticosteroids, Intravenous Immunoglobulin, Plasma Exchange, or Other?
TECFIDERA prescribing information
FGF2 and FGFR1 signaling regulate functional recovery following cuprizone demyelination.

Pages